Half of the public aren’t even aware that conditions like type II diabetes may be preventable.
News
Cediranib trips up in Lynparza combo ovarian cancer trial
When added to Lynparza, the drug didn’t meet the trial’s primary endpoint.
Venclyxto gains approval in Europe
In a trial, the drug in combo with Gazyvaro led to a 65% reduction in the risk of disease worsening or death.
“Two-pronged” DNA repair attack could kill drug-resistant cancers
The new study “establishes the basis for a potentially exciting new approach to treatment.”
Ajovy bags NICE approval
The anti-CGRP preventive therapy is the first of-its-kind to be recommended by NICE.
FDA green lights Opdivo, Yervoy combo for hepatocellular carcinoma
The combo has been granted Accelerated Approval in the US.
Setback for MedDay’s MD1003 as drug fails non-active progressive MS trial
MedDay will review the latest findings in detail “to understand these outcomes to help inform future clinical research in progressive MS and other neurological diseases.”
NICE hits Keytruda with ‘no’ for urothelial cancer
The rejection comes after a review of new evidence collected while the blockbuster was available via the Cancer Drugs Fund.
COVID-19: NHS ‘ramp up’ testing labs as outbreak declared pandemic
As well as testing of people who meet the criteria for being at risk, the NHS and PHE are also carrying out surveillance testing on people in wards and surgeries showing signs of the virus.
Empliciti, Revlimid combo falls short in multiple myeloma
BMS is “disappointed” at the outcome.
DE-122 flops in wet AMD trial
In a trial, the addition of DE-122 to Roche’s Lucentis (ranibizumab) did not improve visual acuity compared to treatment with Lucentis alone.
NICE, Health Technology Wales announce new partnership
The two organisations have detailed plans to work together on planning and information sharing over the assessment of medical technologies.
New genetic test could pick out ‘high risk’ bone marrow cancer patients
Picking out patients whose cancers have high-risk genetic features could help clinicians realise sooner if they’re unlikely to respond to treatment, enabling them to find alternative options as early as possible.
Final chance to enter into CROY 2020
The 2020 Clinical Researcher of the Year – The Americas competition will be closing for entry at midnight this Friday the 13th March.
Thrombocytopenia patients set to get Mulpleo after UK launch
The drug is the first licensed treatment available on the NHS in the UK to treat this condition.
